Medicare Enrolled

Dr. Osama Amro, MD., MS

Nephrology · Seattle, WA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
515 MINOR AVE, Seattle, WA 98104
2063869500
In practice since 2010 (16 years)
NPI: 1154642643 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Amro from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Amro? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Amro

Dr. Osama Amro is a nephrology specialist in Seattle, WA, with 16 years of NPI registration. Based on federal Medicare data, Dr. Amro performed 4,710 Medicare services across 546 unique beneficiaries.

Between the years covered by Open Payments, Dr. Amro received a total of $323,953 from 15 pharmaceutical and/or device companies across 477 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in nephrology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Amro is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 16 years in practice ▲ Top 8% volume in WA $323,953 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,710
Medicare services
Top 8% in WA for nephrology
546
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~294 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Darbepoetin injection (Aranesp) for anemia
An injection of darbepoetin alfa used for non-end-stage renal disease purposes.
3,600 $2 $19
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
238 $91 $312
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
220 $67 $194
Monthly dialysis physician visit
A monthly doctor's visit for patients aged 20 or older who are receiving dialysis treatment.
201 $172 $569
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
182 $101 $275
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
63 $65 $222
Home dialysis services per month
Monthly dialysis treatment provided in the patient's home for individuals aged 20 or older.
62 $249 $829
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
52 $152 $438
Dialysis services for adults, 2-3 visits per month
This code covers dialysis services for patients aged 20 or older who have 2 to 3 physician visits per month.
37 $246 $829
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
29 $144 $511
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
26 $11 $74
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$323,953
Total received (2018-2024)
Avg $46,279/year across 7 years
Top 1% in WA for nephrology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
15
Companies
477
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$301,313 (93.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$21,189 (6.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,451 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$25,239
2023
$69,596
2022
$32,692
2021
$66,719
2020
$28,713
2019
$71,879
2018
$29,115

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Otsuka America Pharmaceutical, Inc.
$24,767
Baxter Healthcare
$165
Mallinckrodt Hospital Products Inc.
$138
Aurinia Pharma U.S., Inc.
$110
Novartis Pharmaceuticals Corporation
$45
AstraZeneca Pharmaceuticals LP
$14
Top 3 companies account for 99.3% of 2024 payments
All-time payments by company (2018-2024) ›
Otsuka America Pharmaceutical, Inc.
$298,529
Otsuka Pharmaceutical Development & Commercialization, Inc.
$12,567
GENZYME CORPORATION
$3,923
Aurinia Pharma U.S., Inc.
$2,869
Bayer HealthCare Pharmaceuticals Inc.
$2,532
NOVARTIS PHARMACEUTICALS CORPORATION
$1,650
Vertex Pharmaceuticals Incorporated
$517
Alexion Pharmaceuticals, Inc.
$470
AstraZeneca Pharmaceuticals LP
$364
Baxter Healthcare
$165
Vifor Pharma, Inc.
$159
Mallinckrodt Hospital Products Inc.
$138
Novartis Pharmaceuticals Corporation
$45
Alnylam Pharmaceuticals Inc.
$19
Travere Therapeutics, Inc.
$6
Top 3 companies account for 97.2% of all-time payments
Associated products mentioned in payments ›
FARXIGA · JYNARQUE · Kerendia · LOKELMA · LUPKYNIS · OXLUMO · Renal - Chronic · SAMSCA · SOLIRIS · TERLIVAZ · TOLVAPTAN · ULTOMIRIS · Veltassa
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (93%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in nephrology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for nephrology in WA.

Looking for a nephrology specialist in Seattle?
Compare nephrologists in the Seattle area by procedure volume, costs, and industry payment transparency.
Browse nephrologists nearby

Geographic Context

Nephrologists within 10 mi
108
Per 100K population
4.8
County median income
$122,148
Nearest hospital
HARBORVIEW MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Amro is a mixed practice specialist, with above-average Medicare volume (top 8% in WA), with speaking/promotional industry engagement in the top 1% of WA peers, with 16 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Amro experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Amro performed 3,600 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Amro receive payments from pharmaceutical companies?
Yes. Dr. Amro received a total of $323,953 from 15 companies across 477 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Amro's costs compare to other nephrologists in Seattle?
Dr. Amro's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Amro) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →